Literature DB >> 30937733

Relugolix: First Global Approval.

Anthony Markham1.   

Abstract

The orally active nonpeptide gonadotropin-releasing hormone (GnRH)-receptor antagonist relugolix (Relumina) is being developed by Takeda and ASKA Pharmaceutical as a treatment for various sex hormone related disorders. Relugolix was recently approved for marketing in Japan as a treatment for symptoms associated with uterine fibroids, and studies evaluating the efficacy of the drug as treatment for endometriosis-associated pain and prostate cancer are currently underway. This article summarizes the milestones in the development of relugolix leading to this first approval for the treatment of symptoms associated with uterine fibroids.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30937733     DOI： 10.1007/s40265-019-01105-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  7 in total

1.  An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Authors:  Mohamed Ali; Hsin-Yuan Chen; Yi-Fen Chiang; Osama A Badary; Shih-Min Hsia; Ayman Al-Hendy
Journal:  Expert Opin Pharmacother       Date:  2022-01-24       Impact factor: 3.889

Review 2.  Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.

Authors:  Manuela Neri; Gian Benedetto Melis; Elena Giancane; Valerio Vallerino; Monica Pilloni; Bruno Piras; Alessandro Loddo; Anna Maria Paoletti; Valerio Mais
Journal:  Int J Womens Health       Date:  2019-10-22

Review 3.  GnRH Antagonists with or without Add-Back Therapy: A New Alternative in the Management of Endometriosis?

Authors:  Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

4.  The novel oral gonadotropin-releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles.

Authors:  Shinnosuke Komiya; Tomoko Tsuzuki-Nakao; Yoshiko Asai; Tomoko Inoue; Yoshiharu Morimoto; Hidetaka Okada
Journal:  Reprod Med Biol       Date:  2022-02-17

5.  Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1-6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare.

Authors:  Nicola J Nasser; Kai Sun; Karen M Scanlon; Mark V Mishra; Jason K Molitoris
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

Review 6.  FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.

Authors:  Aleksandra Sochacka-Ćwikła; Marcin Mączyński; Andrzej Regiec
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

Review 7.  Endometriosis and pain in the adolescent- striking early to limit suffering: A narrative review.

Authors:  Christine B Sieberg; Claire E Lunde; David Borsook
Journal:  Neurosci Biobehav Rev       Date:  2019-12-17       Impact factor: 8.989
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.